黏液样脂肪肉瘤术前放疗剂量降低:非随机对照试验
DOREMY试验是一项前瞻性单组2期非随机对照试验,纳入79例成人非转移性黏液样脂肪肉瘤患者,评估术前36 Gy(2 Gy/次)放疗后手术的病理反应与并发症。77例手术患者中91%出现广泛病理缓解,局部控制率100%,需干预的伤口并发症17%,≥2级毒性14%。提示降低术前放疗剂量有效且肿瘤学安全,并发症低于历史对照。
要点
- 术前36 Gy放疗后91%黏液样脂肪肉瘤获广泛病理缓解
- 局部控制率100%,需干预伤口并发症17%
- ≥2级毒性14%,并发症低于历史对照
核心结论
- DOREMY试验提示黏液样脂肪肉瘤术前放疗剂量降至36 Gy仍有效且肿瘤学安全,并发症低于历史对照。
研究设计与样本
- 前瞻性单组2期非随机对照试验,在欧洲和美国9个三级肉瘤中心开展。
- 纳入79例成人非转移性、活检证实且经易位确认的四肢或躯干黏液样脂肪肉瘤患者。
主要发现
- 77例手术患者中70例(91%;后验均值90.4%;95%最高概率密度区间83.8%-96.4%)出现广泛病理治疗反应。
- 局部控制率为100%。
- 需干预的伤口并发症发生率为17%,≥2级毒性反应发生率为14%。
关键数值与推荐
- 广泛治疗反应定义为肿瘤体积50%或以上含有治疗效应。
- 主要终点为中央审查的病理治疗反应,≥70%切除标本显示广泛反应视为成功。
- 试验方案为术前36 Gy,每日1次2 Gy分割,间隔4周或以上后行根治性手术切除。
临床怎么用
- 对于活检证实且经易位确认的四肢或躯干黏液样脂肪肉瘤,可考虑术前36 Gy(2 Gy/次)放疗后手术。
- 该剂量分割方案可作为黏液样脂肪肉瘤的术前放疗选择,因罕见癌难以开展3期试验。
局限性
- 为非随机单组试验,与历史对照比较时需考虑放疗技术和随访差异。
- 2例患者因合并转移性疾病未行手术切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosensitivity of the myxoid liposarcoma subtype might offer the possibility to reduce morbidity. OBJECTIVE: To assess whether a dose reduction of preoperative radiotherapy for myxoid liposarcoma would result in comparable oncological outcome with less morbidity. DESIGN, SETTING, AND PARTICIPANTS: The Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY) trial is a prospective, single-group, phase 2 nonrandomized controlled trial being conducted in 9 tertiary sarcoma centers in Europe and the US. Participants include adults with nonmetastatic, biopsy-proven and translocation-confirmed myxoid liposarcoma of the extremity or trunk who were enrolled between November 24, 2010, and August 1, 2019. Data analyses, using both per-protocol and intention-to-treat approaches, were conducted from November 24, 2010, to January 31, 2020. INTERVENTIONS: The experimental preoperative radiotherapy regimen consisted of 36 Gy in once-daily 2-Gy fractions, with subsequent definitive surgical resection after an interval of 4 or more weeks. MAIN OUTCOMES AND MEASURES: As a short-term evaluable surrogate for local control, the primary end point was centrally reviewed pathologic treatment response. The experimental regimen was regarded as a success when 70% or more of the resection specimens showed extensive treatment response, defined as 50% or greater of the tumor volume containing treatment effects. Morbidity outcomes consisted of wound complications and late toxic effects. RESULTS: Among the 79 eligible patients, 44 (56%) were men and the median (interquartile range) age was 45 (39-56) years. Two patients did not undergo surgical resection because of intercurrent metastatic disease. Extensive pathological treatment response was observed in 70 of 77 patients (91%; posterior mean, 90.4%; 95% highest probability density interval, 83.8%-96.4%). The local control rate was 100%. The rate of wound complication requiring intervention was 17%, and the rate of grade 2 or higher toxic effects was 14%. CONCLUSIONS AND RELEVANCE: The findings of the DOREMY nonrandomized clinical trial suggest that deintensification of preoperative radiotherapy dose is effective and oncologically safe and is associated with less morbidity than historical controls, although differences in radiotherapy techniques and follow-up should be considered. A 36-Gy dose delivered in once-daily 2-Gy fractions is proposed as a dose-fractionation approach for myxoid liposarcoma, given that phase 3 trials are logistically impossible to execute in rare cancers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02106312.
引用
- Lansu J, Bovée JVMG, Braam P, et al. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. JAMA Oncol. 2021. PMID: 33180100. doi:10.1001/jamaoncol.2020.5865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。